Form 4: Exelixis EVP Sells Shares After RSU Vesting

Exelixis EVP of Commercial, Patrick J. Haley, reported the sale of common stock following the vesting of performance-based restricted stock units.

Summary

• Patrick J. Haley, EVP, Commercial of Exelixis, Inc., reported transactions involving the company's common stock.
• On February 15, 2026, 31,483 shares were withheld by Exelixis to cover taxes related to the vesting of performance-based restricted stock units (RSUs). These RSUs were awarded on March 4, 2022, and performance criteria were certified on January 16, 2025.
• On February 17, 2026, Haley sold 3,036 shares at a weighted average price of $43.84 per share, with prices ranging from $43.80 to $43.84.
• Also on February 17, 2026, an additional 64,778 shares were sold at a weighted average price of $43.50 per share, with prices ranging from $43.50 to $43.64.
• Following these transactions, Haley beneficially owns 381,908 shares of Exelixis common stock, which includes shares from unvested restricted stock units and performance stock units granted on March 31, 2025.
• The reported sales were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine for an executive monetizing vested equity and covering tax obligations, especially given the use of a 10b5-1 plan.

Positives

• The vesting of performance-based restricted stock units indicates that Exelixis, Inc. achieved certain performance criteria as certified by the Compensation Committee on January 16, 2025.
• The sales were conducted under a Rule 10b5-1(c) plan, which suggests pre-planned transactions rather than opportunistic selling, mitigating potential concerns about insider trading.

Negatives

• The sale of 67,814 shares (3,036 + 64,778) by a key executive could be perceived negatively by some investors, although it is a common practice for executives to sell shares to cover taxes and for liquidity after vesting.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are common in the biotechnology and pharmaceutical sectors as executives monetize vested equity compensation. The use of a 10b5-1 plan is a standard practice to manage such transactions transparently and mitigate concerns about opportunistic trading.

Related Party Transactions

• The transactions involve an executive (Patrick J. Haley) of Exelixis, Inc., making them related-party transactions. Specifically, shares were withheld by Exelixis, Inc. to satisfy taxes, and the executive sold shares.

Stakeholder Impact

• Shareholders: May view the executive's sale of shares as a signal, though the 10b5-1 plan mitigates concerns. The reduction in direct beneficial ownership by a key executive could be a minor concern for some.

Key Dates

Recommendation

The filing details routine insider transactions by an executive, including shares withheld for taxes upon RSU vesting and subsequent sales under a pre-arranged 10b5-1 plan. These transactions are common and do not inherently signal a change in the company's fundamental outlook or performance. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient new information to warrant a change in investment thesis.

Keywords

Exelixis, EXEL, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Performance Stock Units, Executive Compensation, Patrick J. Haley, Biotechnology, Pharmaceuticals